Retatrutide Dosage Calculator
LY3437943 (investigational)
Retatrutide (the triple GLP-1/GIP/glucagon agonist, code-named LY3437943) is still investigational. There's no FDA label yet, so the numbers below come from Eli Lilly's phase 2 trials rather than a pharmacy insert. In the obesity trial, people started at 2 mg once weekly and stepped up every 4 weeks or so toward a 4, 8, or 12 mg maintenance dose. The 12 mg group lost about 24% of their body weight by week 48. Enter your vial size and target dose and the calculator tells you exactly what to draw.
Common Retatrutide doses (once weekly)
Concentration
5.00
mg/ml
5000 mcg/ml
Volume per Dose
0.400
ml
Draw this amount
Syringe Draw
40
IU
100-unit insulin syringe
Supply per Vial
5.0
weeks
At 2 mg/week
Draw to
40.0 units
Draw to this line
Retatrutide Titration Schedule & Dose Chart
Syringe units below assume a 10 mg vial in 2 ml of BAC water (5.0 mg/ml). Adjust the calculator above for your own mix.
| Week | Weekly Dose | Volume | Syringe Draw |
|---|---|---|---|
| 1-4 | 2 mg | 0.40 ml | 40 IU |
| 5-8 | 4 mg | 0.80 ml | 80 IU |
| 9-12 | 8 mg | 1.60 ml | 160 IU |
| 13+ | 12 mg | 2.40 ml | 240 IU |
Maximum studied dose: 12 mg once weekly. Step up only if side effects are tolerable.
Retatrutide is investigational and not FDA-approved. These figures come from published clinical-trial data, not a pharmacy label, and are for research and educational purposes only. This is not medical advice.
Retatrutide Dosing FAQ
Research basis
Free 2026 Peptide Cheat Sheet (PDF)
Reconstitution math, concentration charts, half-lives, and vendor links. The reference we wish we had on day one.